Valneva预计2024年收入达到1.696亿欧元（同比增长10%），产品销售额达到1.633亿欧元（同比增长13%）；现金及现金等价物为1.683亿欧元_老虎社区_美港股上老虎

Valneva预计2024年收入达到1.696亿欧元（同比增长10%），产品销售额达到1.633亿欧元（同比增长13%）；现金及现金等价物为1.683亿欧元

财报速递02-18

Valneva公司2024年的销售收入实现了13%的增长（相较于2023年），总收入实现了10%的增长（相较于2023年）。年末强劲的现金头寸为1.683亿欧元。2024年在临床和监管方面取得了显著进展，预计2025年将有多项数据发布、产品批准和标签扩展。2025年的展望反映了稳健的收入增长和积极的商业现金流，以支持战略性的研发投资，同时降低运营现金消耗。

以上内容来自Benzinga Earnings专栏，原文如下：

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)
Strong year-end cash position of €168.3 million
Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025
2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/1161815401?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-18 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161815401","market":"us","top_or_hot":-1,"title":"Valneva预计2024年收入达到1.696亿欧元（同比增长10%），产品销售额达到1.633亿欧元（同比增长13%）；现金及现金等价物为1.683亿欧元","media":"财报速递","content":"Valneva公司2024年的销售收入实现了13%的增长（相较于2023年），总收入实现了10%的增长（相较于2023年）。年末强劲的现金头寸为1.683亿欧元。2024年在临床和监管方面取得了显著进展，预计2025年将有多项数据发布、产品批准和标签扩展。2025年的展望反映了稳健的收入增长和积极的商业现金流，以支持战略性的研发投资，同时降低运营现金消耗。<br><br>以上内容来自Benzinga Earnings专栏，原文如下：<br><html><body><ul><li>Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)</li><li>Strong year-end cash position of €168.3 million</li><li>Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025</li><li>2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&amp;D investments with lower operating cash burn</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva预计2024年收入达到1.696亿欧元（同比增长10%），产品销售额达到1.633亿欧元（同比增长13%）；现金及现金等价物为1.683亿欧元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva预计2024年收入达到1.696亿欧元（同比增长10%），产品销售额达到1.633亿欧元（同比增长13%）；现金及现金等价物为1.683亿欧元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1048278264\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">财报速递 </p>\n<p class=\"h-time\">2025-02-18 14:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\nValneva公司2024年的销售收入实现了13%的增长（相较于2023年），总收入实现了10%的增长（相较于2023年）。年末强劲的现金头寸为1.683亿欧元。2024年在临床和监管方面取得了显著进展，预计2025年将有多项数据发布、产品批准和标签扩展。2025年的展望反映了稳健的收入增长和积极的商业现金流，以支持战略性的研发投资，同时降低运营现金消耗。<br><br>以上内容来自Benzinga Earnings专栏，原文如下：<br><html><body><ul><li>Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)</li><li>Strong year-end cash position of €168.3 million</li><li>Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025</li><li>2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&amp;D investments with lower operating cash burn</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VALN","symbol_name":"Valneva SE","start_time":0,"source_url":"","article_id":"1161815401","we_media_id":"1048278264","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161815401","pubTimestamp":1739861659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"财报速递","introduction":"每日财报追踪","home_visible":1,"id":"1048278264","head_image":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738"},"summary":"Valneva公司2024年的销售收入实现了13%的增长，总收入实现了10%的增长。年末强劲的现金头寸为1.683亿欧元。2024年在临床和监管方面取得了显著进展，预计2025年将有多项数据发布、产品批准和标签扩展。2025年的展望反映了稳健的收入增长和积极的商业现金流，以支持战略性的研发投资，同时降低运营现金消耗。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VALN":"Valneva SE"},"translate_title":"Valneva expects 2024 revenue to reach 169.6 million euros (up 10% year-on-year) and product sales to reach 163.3 million euros (up 13% year-on-year); Cash and cash equivalents of € 168. 3 million","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VALN":0.9},"content_text":"Valneva公司2024年的销售收入实现了13%的增长（相较于2023年），总收入实现了10%的增长（相较于2023年）。年末强劲的现金头寸为1.683亿欧元。2024年在临床和监管方面取得了显著进展，预计2025年将有多项数据发布、产品批准和标签扩展。2025年的展望反映了稳健的收入增长和积极的商业现金流，以支持战略性的研发投资，同时降低运营现金消耗。以上内容来自Benzinga Earnings专栏，原文如下：Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}